Pyxis Oncology's Q1 Net Loss Widens to $23.27M; Cash Runway Extends to Q4 2026
PYXS has more than doubled off its 52-week low of $0.97.
Summary
Pyxis Oncology reported a widened Q1 net loss of $23.27 million, or $0.37 per share, primarily driven by increased clinical trial costs for its lead candidate MICVO. This financial update follows the company's previous 10-K filing which included a 'going concern' warning, underscoring the ongoing financial challenges. The company now expects its cash runway to extend into the fourth quarter of 2026, providing a critical update on its liquidity. This news, coupled with the recent departure of the President, CEO, and CMO in late April, highlights a period of significant operational and financial scrutiny for Pyxis Oncology. Traders will be closely watching for further updates on clinical trial progress and future financing plans given the company's capital needs.
At the time of this announcement, PYXS was trading at $2.54 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $164.6M. The 52-week trading range was $0.97 to $5.55. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.